Modality
Cell Therapy
MOA
PD-1i
Target
MDM2
Pathway
T-cell
MCLFL
Development Pipeline
Preclinical
~Jan 2020
→ ~Apr 2021
Phase 1
~Jul 2021
→ ~Oct 2022
Phase 2
Jan 2023
→ Nov 2031
Phase 2Current
NCT03440377
2,837 pts·FL
2023-01→2031-11·Active
2,837 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-11-045.6y awayPh3 Readout· FL
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2/3
Active
Catalysts
Ph3 Readout
2031-11-04 · 5.6y away
FL
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03440377 | Phase 2/3 | FL | Active | 2837 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| SRP-1135 | Sarepta | Phase 2/3 | MDM2 | |
| ZYM-2450 | Zymeworks | Phase 2 | GLP-1R | |
| ITO-535 | iTeos | NDA/BLA | MDM2 |